QuidelOrtho (NasdaqGS:QDEL) Q3 2025 Earnings Call November 05, 2025 05:00 PM ET Speaker1Welcome to the QuidelOrtho third quarter 2025 financial results conference call and webcast. At this time, all participant lines are in a listen-only mode. For those of you participating in the conference call, there will be an opportunity for your questions at the end of today's prepared remarks. Please note this conference call is being recorded. An audio replay of the conference call will be available on the company's ...

November 5, 2025 QuidelOrtho Third Quarter 2025 Financial Results QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 2 Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, includi ...

Exhibit 99.1 QuidelOrtho Reports Third Quarter 2025 Financial Results ― Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ― ― Successful completion of debt refinancing, enhancing financial flexibility through improved terms and reduced amortization obligations ― ― Full-year 2025 revenue and adjusted EBITDA guidance ranges narrowed; adjusted diluted EPS updated to reflect debt refinancing ― November 5, 202 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Accessibility StatementSkip Navigation SAN DIEGO, Oct. 23, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 52 of its Science Bytes podcast, featuring George Wierschem, MBA, MT(ASCP), Senior Global Product Manager – Informatics. Continue Reading George Wierschem, MBA, MT(ASCP), Senior Global Product Manager – Informatics QuidelOrtho Science Bytes Episode 52: The Power of Informatics in Clinical Decision-Making In the episode titled "T ...

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decision ...

Accessibility StatementSkip Navigation Missing Formulas Join Us at AABB The MTS DAT Card completes QuidelOrtho's gel-based solution for direct antiglobulin testing. When paired with the ORTHO VISIONâ"¢ Platform, it combines proven column agglutination technology with advanced software capabilities – including reflex testing and as-needed quality control – to help laboratories deliver faster, more reliable results for patients who depend on timely transfusion decisions. "The AABB Annual Meeting brings togeth ...

Key Takeaways QDEL launches the QUICKVUE Influenza SARS Test, expanding its respiratory solutions portfolio.QuidelOrtho's test detects flu A, flu B and SARS-CoV-2 antigens from one sample with 10-minute results.The launch supports QDEL's Molecular Diagnostics and Point of Care units across U.S. clinical settings.Last week, QuidelOrtho Corporation (QDEL) announced the availability of QUICKVUE Influenza + SARS Test. The CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay is the latest addition to the c ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Contrarian Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity market showcased a significant recovery during the quarter, rising 23% from low to end the quarter at a record high. U.S. large-cap stocks gained 11.1% in the quarter, and within the large-cap category, growth stocks outperformed value stocks. In this environment, the fund returned 16.42% (net) during the quarter, exceeding ...

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of innovative in vitro diagnostic technologies, is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency dep ...